Raimon Roura - Grifols SA Non-Member Secretary of the Board
| GIFLF Stock | USD 8.46 0.00 0.00% |
Executive
Mr. Raimon Grifols Roura serves as CoChief Executive Officer, Executive Director of Grifols, S.A. since January 1, 2017. He is Associate Partner of the law firm Osborne Clarke in Spain and Board Member of Squadron Reinsurance Ltd, Marca Grifols SL and Arrahona Optimus SL, as well as Patron of Probitas Fundacion Privada. He is a member of the administration bodies of several companies within the Grifols Group. From 2001 to 2015 he held the role of nonmember secretary of the Board of Directors of Grifols, S.A., serving as Director and ViceSecretary of the Board of Directors since 2015. In May 2016 the Board accepted his resignation as vice secretary. He holds a Bachelors degree in Law from Universidad de Barcelona. since 2017.
| Age | 59 |
| Tenure | 7 years |
| Phone | 34 93 571 02 21 |
| Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0155 % which means that it generated a profit of $0.0155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0182 %, meaning that it generated $0.0182 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Roy Papatheodorou | Sanofi ADR | 46 | |
| F Hoffmann | Roche Holding Ltd | N/A | |
| Nuria Barnes | Grifols SA ADR | N/A | |
| Susan MD | AstraZeneca PLC ADR | 58 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Thomas Larsen | AstraZeneca PLC ADR | N/A | |
| Steven Baert | Novartis AG ADR | 45 | |
| Natalie Bickford | Sanofi ADR | 54 | |
| Jeffrey George | Novartis AG ADR | 41 | |
| Samir Shah | Novartis AG ADR | N/A | |
| Stephan Feldhaus | Roche Holding Ltd | 56 | |
| Adrian Kemp | AstraZeneca PLC ADR | N/A | |
| Gottlieb Keller | Roche Holding Ltd | 64 | |
| Eva Tubau | Grifols SA ADR | N/A | |
| Sophie KornowskiBonnet | Roche Holding Ltd | 54 | |
| Felix Ehrat | Novartis AG ADR | 60 | |
| George Gunn | Novartis AG ADR | 63 | |
| Pierre Chancel | Sanofi ADR | 67 | |
| William Pao | Roche Holding Ltd | 51 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| James Sabry | Roche Holding Ltd | 59 | |
Management Performance
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0155 |
Grifols SA Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antonio Pares, Director of Planning and Control | ||
| Peter Allen, Chairman of Hospital OPS Division | ||
| Carsten Schroeder, President Of The Diagnostic Division | ||
| Albert Roura, CEO of Laboratorios Grifols SA | ||
| Jose Garcia, Director General De Laboratorios Grifols | ||
| Lafmin Morgan, President Of The Bioscience And Hospital Division | ||
| Juan Roura, Vice President of Production, Executive Director | ||
| Eva Tubau, Chief Scientific Officer | ||
| Anna Lluch, Independent Director | ||
| Carlos Fernandez, Deputy Industrial Vice President | ||
| Jose Gras, Director, Representative of Thorthol Holdings BV | ||
| Maria Llano, Chief Officer | ||
| Edgar Jannotta, Independent Director | ||
| Vicente Torre, CTO | ||
| Mateo Humbert, Director of Human Resources | ||
| Montserrat Calvo, Chief Administrative Officer, Controller | ||
| Montserrat Llamas, Chief Officer | ||
| Ramon Roca, Vice-President of Marketing and Sales and Executive Director | ||
| Vctor Deu, CoCEO Director | ||
| David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
| Victor Deu, Co-CEO, Executive Director | ||
| Luis Bobadilla, Independent Director | ||
| Inigo Mardones, Director | ||
| Thomas Glanzmann, Director | ||
| Carina Lazaro, Independent Director | ||
| Joel Abelson, President of North America Commercial Division of Grifols Inc | ||
| Steven Mayer, Director | ||
| Jose Fulla, CEO of Diagnostic Industrial Group | ||
| Javier Ribes, CEO of Instituto Grifols SA | ||
| Alfredo Guerra, CFO and Corporate VP | ||
| Raimon Roura, Non-Member Secretary of the Board | ||
| Miguel Montblanch, Chariman of Global Operations Network | ||
| Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee | ||
| Brett Ingersoll, Director | ||
| Shinji Wada, President of Plasma Centers of Grifols Inc | ||
| Tomas Gelabert, Director | ||
| Nuria Lapea, Risk Treasury | ||
| M Tubau, Co Affairs | ||
| Steven JD, Ex Chairman | ||
| Marla Salmon, Independent Director | ||
| Nuria Barnes, Non-Member Assistant Secretary of the Board | ||
| Gregory Rich, President of Grifols Inc and Subsidiaries in the US | ||
| Belen Morenes, Independent Director | ||
| Nuria Lapena, Director of Shareholder and Investor Relations |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0155 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 16.07 B | |||
| Shares Outstanding | 422.18 M | |||
| Shares Owned By Insiders | 30.57 % | |||
| Shares Owned By Institutions | 30.49 % | |||
| Price To Earning | 9.52 X | |||
| Price To Book | 1.04 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grifols SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Grifols Pink Sheet analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |